Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Liabilities (2020 - 2023)

Kymera Therapeutics (KYMR) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $8000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Other Non-Current Liabilities fell 96.88% to $8000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $8000.0, a 96.88% decrease, with the full-year FY2022 number at $248000.0, up 275.76% from a year prior.
  • Other Non-Current Liabilities was $8000.0 for Q3 2023 at Kymera Therapeutics, down from $230000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $273000.0 in Q1 2022 to a low of $8000.0 in Q3 2023.
  • A 4-year average of $161166.7 and a median of $165000.0 in 2020 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 275.76% in 2022, then crashed 96.88% in 2023.
  • Kymera Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2020, then tumbled by 34.0% to $66000.0 in 2021, then skyrocketed by 275.76% to $248000.0 in 2022, then crashed by 96.77% to $8000.0 in 2023.
  • Per Business Quant, the three most recent readings for KYMR's Other Non-Current Liabilities are $8000.0 (Q3 2023), $230000.0 (Q2 2023), and $237000.0 (Q1 2023).